Lecigimon

Entacapone, Levodopa, Carbidopa, the active ingredients in Lecigimon, are a combination (MAO‑B inhibitor, DOPA decarboxylase inhibitor, dopamine precursor) presented as a combination tablet for intestinal use. It is indicated for the treatment of Parkinson's disease and related motor fluctuations in adult patients. GNH USA supplies Lecigimon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lecigimon, a combination therapy for Parkinson’s disease, is indicated for: - Parkinson's disease: improves motor symptoms by increasing central dopamine levels. - Motor fluctuations in Parkinson's disease: reduces OFF time and enhances ON time. - Adjunct therapy for levodopa‑treated patients: stabilizes levodopa plasma concentrations and prolongs its clinical effect.

Lecigimon may cause a range of adverse reactions. Patients should be informed of both common and serious possibilities.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Dyskinesia: involuntary movements, especially at higher levodopa doses. - Orthostatic hypotension: dizziness upon standing. - Constipation: reduced bowel motility. - Dizziness: sensation of light‑headedness. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Severe liver injury: elevated transaminases or hepatic failure. - Neuroleptic malignant syndrome: high fever, muscle rigidity, autonomic instability. - Severe allergic reactions: rash, angioedema, anaphylaxis. - Hyperpyrexia: dangerously high body temperature. - Severe depression or suicidal thoughts. - Hallucinations: visual or auditory disturbances.

Before initiating Lecigimon, clinicians should consider several safety measures. - Monitor hepatic function: assess liver enzymes periodically. - Assess for dyskinesia: adjust levodopa dose if excessive movements develop. - Caution in elderly patients: increased risk of orthostatic hypotension and confusion. - Avoid in patients with narrow‑angle glaucoma: may exacerbate intra‑ocular pressure. - Review concomitant MAO‑B inhibitors: risk of hypertensive crisis. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lecigimon can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: may precipitate hypertensive crisis. - Anticholinergic agents: can increase anticholinergic burden and cognitive impairment. - Dopamine agonists: may potentiate dyskinesia and psychosis.

Moderate Interactions (Monitor Closely): - Antihypertensive drugs: may enhance hypotensive effects. - Iron or calcium supplements: can reduce levodopa absorption if taken simultaneously. - High‑protein meals: may compete with levodopa transport, decreasing its bioavailability.